
    
      Participants will received 6 cycles every 21 days with a follow-up period of 24 months.

      CT-Scan after 3 cycles and at the end of the treatment will be used to assess treatment
      response, established with Cheson criteria in 1999.

      Principal objective is to obtain an overall response rate of 60% (corresponding to an
      increased of 15% of the rituximab-gemcitabine-oxaliplatine regimen's overall response rate).

      Secondaries objectives are to value toxicity, progression free survival and overall survival.
    
  